ライフサイエンスコーパス: vesicular monoamine transporter

1 tonin transporter; and SLC18A2, encoding the vesicular monoamine transporter.

2 calized within the nerve varicosities by the vesicular monoamine transporter.

3 nd in vivo binding of these compounds to the vesicular monoamine transporter.

4 n vitro and in vivo for binding to the brain vesicular monoamine transporter.

5 mine neurons because of the apparent lack of vesicular monoamine transporters.

6 Our results demonstrate that the presynaptic vesicular monoamine transporter 1 (VMAT1) Thr136Ile (rs1

7 Both vesicular monoamine transporter 1 and 2 contain several

8 gic terminals, using a ligand for the type 2 vesicular monoamine transporter, (+)-[11C]dihydrotetrabe

9 mine transporter, serotonin transporter, and vesicular monoamine transporter 2 (like cocaine and meth

10 In this study, we used mice heterozygous for vesicular monoamine transporter 2 (VMAT2 +/- mice) to de

11 ity of mice lacking the neuronal form of the vesicular monoamine transporter 2 (VMAT2) affords the op

12 TH1-S31E associated with vesicular monoamine transporter 2 (VMAT2) and alpha-synu

13 affinity dopamine transporter (DAT), and the vesicular monoamine transporter 2 (VMAT2) as assessed 2-

14 Vesicular monoamine transporter 2 (VMAT2) catalyzes tran

15 Because the location of vesicular monoamine transporter 2 (VMAT2) defines the se

16 genic mouse with a hypomorphic allele of the vesicular monoamine transporter 2 (Vmat2) gene by gene t

17 y monoamines, we have disrupted the neuronal vesicular monoamine transporter 2 (VMAT2) gene.

18 The vesicular monoamine transporter 2 (VMAT2) has sequence h

19 -cell mass (BCM) in the pancreas showed that vesicular monoamine transporter 2 (VMAT2) is highly expr

20 The vesicular monoamine transporter 2 (VMAT2) is localized p

21 We previously reported that the vesicular monoamine transporter 2 (VMAT2) is physically

22 lase (TH) neurons projecting to the LHb lack vesicular monoamine transporter 2 (VMAT2) mRNA, and ther

23 ng the transcriptional activation of the rat vesicular monoamine transporter 2 (VMAT2) promoter in ga

24 scent false neurotransmitter 200 (FFN200), a vesicular monoamine transporter 2 (VMAT2) substrate that

25 Vesicular monoamine transporter 2 (VMAT2) transports mon

26 levels of the dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) were increased

27 (BB) diabetic rats, using antibodies against vesicular monoamine transporter 2 (VMAT2), a marker of s

28 d Pb-exposed mice were immunostained for the vesicular monoamine transporter 2 (VMAT2), serotonin (5-

29 bination to generate mutant mice lacking the vesicular monoamine transporter 2 (VMAT2), the predomina

30 produce norepinephrine (NE) and contain the vesicular monoamine transporter 2 (VMAT2), which package

31 th tracers for the serotonin transporter and vesicular monoamine transporter 2 (VMAT2).

32 ontained both vesicular transporters for DA [vesicular monoamine transporter 2 (VMAT2)] and GABA [ves

33 The vesicular monoamine transporter 2 (VMAT2, SLC18A2) takes

34 The vesicular monoamine transporter 2 (VMAT2; SLC18A2) is re

35 omosome (BAC)-mediated overexpression of the vesicular monoamine transporter 2 (VMAT2; Slc18a2).

36 tion by a mutation in SLC18A2 (which encodes vesicular monoamine transporter 2 [VMAT2]).

37 e varicosities in the outer retina possessed vesicular monoamine transporter 2 and vesicular GABA tra

38 ly smaller than the dopamine transporter and vesicular monoamine transporter 2 defects, suggesting up

39 ing high-fidelity imaging of pHluorin-tagged vesicular monoamine transporter 2 in dopamine neurons, w

40 ine (NBI-98854) is a novel, highly selective vesicular monoamine transporter 2 inhibitor that demonst

41 Vesicular monoamine transporter 2 is important for the a

42 SLC18A2 encodes the vesicular monoamine transporter 2 protein that regulates

43 TH(+) cells expressed both VMAT2 (vesicular monoamine transporter 2) and VGAT (vesicular G

44 gold electron microscopy detection of VMAT2 (vesicular monoamine transporter 2) establish the presenc

45 odds ratio (OR)=1.4, p=2.1E-05) in SLC18A2 (vesicular monoamine transporter 2).

46 emission tomography (PET) radioligand to the vesicular monoamine transporter 2, (VMAT2), [(11)C]dihyd

47 on-enriched genes tyrosine hydroxylase (TH), vesicular monoamine transporter 2, dopamine transporter

48 with the PET ligands, indicating that these vesicular monoamine transporter 2-directed ligands did n

49 ither vesicular acetylcholine transporter or vesicular monoamine transporter 2.

50 [2,1-a]isoquinolin-2-ol ((18)F-AV-300)} bind vesicular monoamine transporter 2.

51 tyrosine hydroxylase, the DA transporter or vesicular monoamine transporter 2.

52 In the brain, the vesicular monoamine transporter-2 (VMAT(2)) is responsib

53 ofiles of tyrosine hydroxylase (TH), DAT and vesicular monoamine transporter-2 (VMAT) in the striatum

54 s vesicular [3H]DA uptake and binding of the vesicular monoamine transporter-2 (VMAT-2) ligand dihydr

55 Vesicular monoamine transporter-2 (VMAT-2) plays a criti

56 ydrotetrabenazine (DTBZ) binding site on the vesicular monoamine transporter-2 (VMAT2) and their abil

57 ctivity was abolished in the presence of the vesicular monoamine transporter-2 (VMAT2) inhibitor rese

58 nd equatorial geometry, respectively, of the vesicular monoamine transporter-2 (VMAT2) inhibitor, lob

59 roscopic immunocytochemistry to localize the vesicular monoamine transporter-2 (VMAT2), a novel marke

60 n of an efficient relay between SERT and the vesicular monoamine transporter-2 (VMAT2).

61 ot accumulated into synaptic vesicles by the vesicular monoamine transporter-2 (VMAT2).

62 Furthermore, DAT and vesicular monoamine transporter-2 expressions were simil

63 y of fixed doses of deutetrabenazine-a novel vesicular monoamine transporter-2 inhibitor-in patients

64 acid decarboxylase, the DA transporter, and vesicular monoamine transporter-2 with EGFP in midbrain

65 s regulating dopamine synthesis and release: vesicular monoamine transporter-2, tyrosine hydroxylase,

66 ABA, the GABA vesicular transporter, and the vesicular monoamine transporter-2.

67 synaptic vesicles by specific transporters (vesicular monoamine transporter-2; VMAT2) using energy f

68 Binding to the vesicular monoamine transporter, a measure of total dopa

69 tron emission tomography imaging of striatal vesicular monoamine transporters and 11C-Pittsburgh comp

70 tron emission tomography imaging of striatal vesicular monoamine transporters and cerebrocortical dep

71 Vesicular monoamine transporters are known to transport

72 ivatives displayed in vitro affinity for the vesicular monoamine transporter binding site in rat brai

73 The vesicular monoamine transporter can protect against toxi

74 n vivo, we used a mutation in the Drosophila vesicular monoamine transporter (dVMAT) as a sensitized

75 erminal trafficking domain of the Drosophila vesicular monoamine transporter (DVMAT), which is requir

76 ve characterized mutations in the Drosophila vesicular monoamine transporter (dVMAT), which is requir

77 wn that mice with a 95% genetic reduction in vesicular monoamine transporter expression (VMAT2-defici

78 A second isoform of the human vesicular monoamine transporter (hVMAT) has been cloned

79 ter (hVAChT) and the neuronal isoform of the vesicular monoamine transporter (hVMAT2) are differentia

80 the large intraluminal loop of the neuronal vesicular monoamine transporter (hVMAT2-loop) as probes

81 CGRP-, SP-, and vesicular monoamine transporter-immunostained neurites a

82 benazine is a high-affinity inhibitor of the vesicular monoamine transporter in mammalian brain.

83 ansporter, and the presence of both types of vesicular monoamine transporters in the exocrine cells o

84 Reserpine, a vesicular monoamine transporter inhibitor, had no effect

85 ents by administration of the VMAT-2 (type-2 vesicular monoamine transporter) inhibitor tetrabenazine

86 Effects of vesicular monoamine transporter inhibitors on catecholam

87 PHEN and D2-PHEN was assessed by inhibiting vesicular monoamine transporter-mediated storage into ve

88 Vesicular monoamine transporters package monoamine neuro

89 ntration of a stable presynaptic marker, the vesicular monoamine transporter protein (VMAT2), was qua

90 haracterized bacterial homologues of the rat vesicular monoamine transporter (rVMAT2).

91 Molecular cloning of vesicular monoamine transporters shows sequence similari

92 , its metabolites, and the expression of the vesicular monoamine transporter, suggesting a decrease i

93 ce P (SP) (sensory C and A delta fibers) and vesicular monoamine transporter (sympathetic fibers).

94 immunostaining for VMAT2, an isoform of the vesicular monoamine transporter that loads catecholamine

95 te that when quantal size is altered via the vesicular monoamine transporter the concentration of cat

96 n which DA is efficiently channeled from the vesicular monoamine transporter to membranous DbetaM for

97 l regulation of decarboxylase activity (FD), vesicular monoamine transporter type 2 (DTBZ), and dopam

98 Vesicular monoamine transporter type 2 (VMAT2) imaging w

99 rabenazine ([(11)C]DTBZ) binding to striatal vesicular monoamine transporter type 2 (VMAT2) in cocain

100 The vesicular monoamine transporter type 2 (VMAT2) is coexpr

101 e whether sequestration by the intracellular vesicular monoamine transporter type 2 (VMAT2) occurs, m

102 The vesicular monoamine transporter type 2 (VMAT2) packages

103 emistry showed that D(3) dopamine receptors, vesicular monoamine transporter type 2 (VMAT2), and dopa

104 ((18)F-DTBZ), a novel radiotracer targeting vesicular monoamine transporter type 2 (VMAT2), has been

105 eurons, autoradiographic measures of DAT and vesicular monoamine transporter type 2 (VMAT2), striatal

106 In particular, the vesicular monoamine transporter type 2 (VMAT2), which is

107 Vesicular monoamine transporter type 2 and benzodiazepin

108 Vesicular monoamine transporter type 2 and benzodiazepin

109 ET images demonstrated that the reduction of vesicular monoamine transporter type 2 availability was

110 The mean reductions of vesicular monoamine transporter type 2 density for the c

111 Striatal vesicular monoamine transporter type 2 expression in dem

112 erase and [(11)C]dihydrotetrabenazine (DTBZ) vesicular monoamine transporter type 2 positron emission

113 ic resonance and [(11)C]dihydrotetrabenazine vesicular monoamine transporter type 2 positron emission

114 was confirmed by [(11)C]dihydrotetrabenazine vesicular monoamine transporter type 2 positron emission

115 [(11) C]dihydrotetrabenazine (DTBZ; reflects vesicular monoamine transporter type 2), ex vivo quantif

116 future in vivo measurements of the striatal vesicular monoamine transporter type 2.

117 icles by one of two proton-amine exchangers, vesicular monoamine transporters type 1 and 2 (VMAT1 and

118 postmortem studies have shown low levels of vesicular monoamine transporter, type 2 (VMAT2), the mem

119 that acute pharmacological inhibition of the vesicular monoamine transporter (VMAT) blocks amphetamin

120 have exploited the broad requirement of the vesicular monoamine transporter (VMAT) for the vesicular

121 Packaging by the vesicular monoamine transporter (VMAT) is essential for

122 Overexpression of the vesicular monoamine transporter (VMAT) rescued the dopam

123 responsive FFNs) as novel probes that act as vesicular monoamine transporter (VMAT) substrates and ra

124 rs for the bovine adrenal chromaffin granule vesicular monoamine transporter (VMAT) that have been pr

125 reserpine, a small-molecule inhibitor of the vesicular monoamine transporter (VMAT) that repackages m

126 icular acetylcholine transporter (VAChT) and vesicular monoamine transporter (VMAT) transport neurotr

127 Vesicular monoamine transporter (VMAT), a member of the

128 ore, parachloroamphetamine (pCA), acting via vesicular monoamine transporter (VMAT), and a charged VM

129 ing pharmacological blockers of SERT and the vesicular monoamine transporter (VMAT), we have identifi

130 lase (TH), dopamine transporter (DAT) or the vesicular monoamine transporter (VMAT).

131 is one of the best known substrates for the vesicular monoamine transporter (VMAT).

132 d independently of synaptic targeting of the vesicular monoamine transporter (VMAT).

133 inimum by continuous pumping activity of the vesicular monoamine transporter (VMAT)2.

134 sion of norepinephrine transporter (NET) and vesicular monoamine transporter (VMAT-1) was evaluated i

135 Antisera against the vesicular monoamine transporters VMAT1 and VMAT2 demonst

136 sferase (COMT), monoamine oxidase-A (MAO-A), vesicular monoamine transporter (VMAT1,2) and chromogran

137 sfection to increase expression of the brain vesicular monoamine transporter VMAT2 and presynaptic am

138 amate in vitro and in vivo, we have used the vesicular monoamine transporter VMAT2 and the vesicular

139 icles (LDCVs) depends on localization of the vesicular monoamine transporter VMAT2 to LDCVs.

140 stead, GABA release requires activity of the vesicular monoamine transporter VMAT2, which is the vesi

141 choline transporter (VAChT) and the neuronal vesicular monoamine transporter (VMAT2) as important mol

142 ne D1-like and D2-like receptors, and type 2 vesicular monoamine transporter (VMAT2) binding sites we

143 and inhibits dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) function.

144 The subcellular localization of the vesicular monoamine transporter (Vmat2) mRNA corresponds

145 The hypothesis that human cocaine users lose vesicular monoamine transporter (VMAT2) protein was test

146 The brain vesicular monoamine transporter (VMAT2) pumps monoamine

147 To identify residues in the neuron-specific vesicular monoamine transporter (VMAT2) responsible for

148 the regional cerebral density of the type 2 vesicular monoamine transporter (VMAT2) using positron e

149 The vesicular monoamine transporter (VMAT2) was absent befor

150 Confocal microscopy analysis showed that the vesicular monoamine transporter (VMAT2) was decreased in

151 atory polymorphisms in the brain form of the vesicular monoamine transporter (VMAT2) which affect its

152 Type 2 vesicular monoamine transporter (VMAT2), found in the br

153 rotetrabenazine, a new ligand for the type 2 vesicular monoamine transporter (VMAT2), with positron e

154 tanserin and TBZ are both antagonists of the vesicular monoamine transporter (VMAT2).

155 Type 2 vesicular monoamine transporters (VMAT2) are expressed i

156 The two closely related vesicular monoamine transporters (VMATs) 1 and 2 differ

157 The vesicular monoamine transporters (VMATs) 1 and 2 show cl

158 rong sequence similarity, and studies of the vesicular monoamine transporters (VMATs) indicate prefer

159 esicles (SLMVs), whereas the closely related vesicular monoamine transporters (VMATs) localize prefer

160 The vesicular monoamine transporters (VMATs) package monoami

161 Vesicular monoamine transporters (VMATs) translocate mon

162 Molecular cloning has identified two vesicular monoamine transporters (VMATs), one expressed

163 norhabditis elegans homolog of the mammalian vesicular monoamine transporters (VMATs); it is 47% iden

164 rotetrabenazine, a new ligand for the type 2 vesicular monoamine transporter, with positron emission